KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire
The genetics of primary dysmenorrhea: a systematic review.
Dysmenorrhea is the most common gynaecological condition in women of reproductive age. Approximately 90% of cases are primary dysmenorrhea (PDM) which is not associated with underlying pathology. Dysmenorrhea can have …
Beyond growing teratoma syndrome: post-treatment manifestations and diagnostic challenges following ovarian immature teratoma.
Growing teratoma syndrome (GTS) is a rare condition classically associated with platinum-based chemotherapy for malignant ovarian germ cell tumors. However, post-treatment findings following ovarian immature teratoma may represent a broader …
Immune-epigenetic-metabolic crosstalk: attempting to unravel the multidimensional mechanisms of immune evasion in endometriosis.
The survival of ectopic endometrial lesions in endometriosis critically depends on their ability to evade immune recognition and clearance by the host, a process known as immune evasion. Recent studies …